Ralliant Corporation (RAL) to Issue Quarterly Dividend of $0.05 on March 23rd

Ralliant Corporation (NYSE:RAL) declared a quarterly dividend on Thursday, January 29th. Stockholders of record on Monday, March 9th will be given a dividend of 0.05 per share on Monday, March 23rd. This represents a c) annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, March 9th.

Ralliant Trading Down 3.5%

Shares of RAL stock opened at $44.74 on Friday. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.38. Ralliant has a 12-month low of $37.27 and a 12-month high of $57.02. The stock has a market capitalization of $5.00 billion and a P/E ratio of 22.83. The firm’s 50 day moving average is $48.94 and its 200 day moving average is $46.64.

Ralliant (NYSE:RAL) last announced its earnings results on Wednesday, February 4th. The company reported $0.69 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.02. The company had revenue of $554.60 million for the quarter, compared to analysts’ expectations of $543.04 million. The company’s revenue was up 1.2% on a year-over-year basis. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on RAL. Royal Bank Of Canada reduced their price objective on Ralliant from $52.00 to $41.00 and set a “sector perform” rating for the company in a research report on Friday, February 6th. Morgan Stanley reissued an “overweight” rating and issued a $45.00 target price on shares of Ralliant in a research report on Friday, February 6th. Citigroup cut their price target on Ralliant from $61.00 to $51.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Vertical Research raised shares of Ralliant from a “hold” rating to a “buy” rating and set a $45.00 price target for the company in a research report on Friday, February 6th. Finally, Oppenheimer lowered their price objective on shares of Ralliant from $60.00 to $50.00 and set an “outperform” rating on the stock in a research note on Friday, February 6th. Seven analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $50.50.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.